HALO
Halozyme Therapeutics Inc
109.90$
+2.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -136.9% | – | – | +440.0% | -19.8% | +61.8% | +23.3% | +36.0% | |
| – | -4.8% | +43.7% | -10.3% | +10.5% | +70.4% | -19.3% | -8.7% | +1,817.9% | +47.6% | +4.5% | -0.7% | |
| – | +36.4% | +22.8% | +19.9% | +16.4% | -2.6% | -50.5% | +21.0% | +17.2% | +50.1% | +18.5% | +18.9% | |
| – | +40.1% | +53.1% | +39.8% | -23.2% | +1.3% | -54.6% | -792.2% | – | – | – | – | |
| – | -27,927.4% | – | +21.9% | -128.4% | – | – | – | -3,055.8% | – | – | – | |
| – | +72.5% | +32.9% | -57.0% | +245.4% | -13.4% | -38.0% | -41.8% | +230.1% | +218.0% | -30.1% | -34.8% | |
| – | – | -1,403.8% | +113.3% | – | -322.6% | – | -618.5% | +19.9% | -80.1% | +171.1% | +107.8% | |
| – | – | – | – | – | – | +345.7% | -80.2% | – | – | – | – | |
| – | -88.6% | -85.8% | +7,816.9% | -90.7% | -1,557.8% | -24.9% | +133.2% | -42.9% | +101.2% | -37.9% | +36.9% | |
| – | +0.0% | +0.0% | -110.8% | +384.6% | – | -105.8% | – | +48.5% | -102.2% | -100.0% | – | |
| – | -88.6% | +1,050.0% | -12.6% | -148.5% | – | -169.4% | – | +365.4% | -212.6% | -46.4% | -61.1% | |
| – | -153.2% | – | +334.5% | -208.7% | – | -55.8% | -205.3% | – | -200.7% | – | – | |
| – | – | – | – | -140.8% | – | – | +462.8% | -21.0% | +58.6% | +25.5% | +37.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.